MedTrace Logo

Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy

NCT06478472 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-07-29

No results posted yet for this study

Summary

Orelabrutinib combined with rituximab (OR) therapy were used to assess the efficacy and safety for newly diagnosed Marginal zone cell lymphoma

Conditions

Interventions

DRUG

Orelabrutinib in combination with rituximab

Induction Phase: Orelabrutinib + rituximab for a total of 6 cycles of 28 days each Obrutinib (O) 150mg oral d1-28 Rituximab (R) 375mg/m2 IV d0 Maintenance phase: Orelabrutinib 150mg po qd 24 cycles of 28 days each

Sponsors & Collaborators

  • The First Hospital of Jilin University

    collaborator OTHER

  • Fujian Cancer Hospital

    collaborator OTHER_GOV

  • Guangdong Provincial People's Hospital

    collaborator OTHER

  • Nanfang Hospital, Southern Medical University

    collaborator OTHER

  • The Second Affiliated Hospital of Dalian Medical University

    collaborator OTHER

  • Jiangxi Provincial Cancer Hospital

    collaborator OTHER

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    collaborator OTHER

  • Shaanxi Provincial Cancer Hospital

    collaborator OTHER

  • Chinese PLA General Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Xiamen University

    lead OTHER

Principal Investigators

  • Bing Xu · The First Aiffiliated hosptical of xiamen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-23
Primary Completion
2027-06-23
Completion
2027-06-23

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06478472 on ClinicalTrials.gov